Summary:
This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.
Qualified Participants Must:
• Have a diagnosis of COPD confirmed at first visit
•
Current or former smoker of at least 10 pack-years (1 pack per day for 10 years, half a pack for 20 years, etc...)
•
At least one Cardiovascular disease risk factor (heart attack, bypass graft, coronary stenosis, chronic heart failure, peripheral artery disease, hypertension, Type 2 Diabetes, dyslipidemia, Chronic Kidney Disease, moderate coronary artery calcification score, etc...) Please inquire if unknown
•
Additional criteria may apply
Qualified Participants May Receive:
$230 for your first visit. Up to a total of $1,260 if you are eligible and complete the entire study.